Want to see HK:2315 full AI Analyst Report?
2315 Stock Chart & Stats
HK$28.70
-HK$0.07(-0.93%)
At close: 4:00 PM EST
HK$28.70
-HK$0.07(-0.93%)
Day’s Range― - ―
52-Week RangeHK$20.30 - HK$70.15
Previous CloseN/A
Volume49.50K
Average Volume (3M)488.12K
Market Cap
HK$19.67B
Enterprise ValueHK$13.44K
Total Cash (Recent Filing)HK$1.56B
Total Debt (Recent Filing)HK$584.09M
Price to Earnings (P/E)100.0
Beta1.19
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.43
Shares Outstanding110,781,920
10 Day Avg. Volume755,126
30 Day Avg. Volume488,121
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)5.83
Price to Sales (P/S)9.20
P/FCF Ratio44.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$62.00Price Target Upside116.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.79
Revenue Forecast (FY)HK$1.92B
Bulls Say, Bears Say
Bulls Say
Revenue Scale And High Gross MarginsMeaningful multi-year revenue scaling combined with consistently high gross margins indicates a scalable service and platform business. Durable unit economics support reinvestment in R&D and client services, improving long-term cash generation and margin sustainability.
Recent Profitability And Improving ReturnsThe shift to sustained profitability and expanded margins signals operational leverage from higher revenue and margin mix. Improved returns (ROE ~8% in 2025) enhance self-funding ability for development programs and reduce reliance on external financing over the medium term.
Proprietary Discovery Platform And Diversified Revenue ModelThe proprietary genetically engineered animal platforms create a competitive moat in antibody discovery. A mix of fee-for-service, collaborations, licensing and milestone revenue delivers diversified, repeatable demand from pharma/biotech partners, supporting durable revenue streams.
Bears Say
Inconsistent Free Cash Flow TrendsAlthough operating and free cash flow turned positive, a 16.6% FCF decline in 2025 and earlier multi-year outflows indicate uneven cash generation. This inconsistency raises financing and runway risk if revenue or partner payments fall, limiting strategic flexibility.
Earnings Stability Risk From Prior LossesHistoric multi-year losses before the recent inflection demonstrate that profitability is not yet proven across cycles. Biotech services and milestone revenues can be lumpy; absent consistent contract pipelines, earnings could revert, increasing volatility in cash and margins.
Capital Structure And Equity VolatilityWhile leverage has improved materially, the balance sheet and equity levels have shown notable year-to-year swings. Such capital structure volatility can signal prior reliance on financing, and could lead to dilution or constrained leverage capacity if cash generation weakens.
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H News
2315 FAQ
What was Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s price range in the past 12 months?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H lowest stock price was HK$20.30 and its highest was HK$70.15 in the past 12 months.
What is Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s market cap?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s market cap is HK$19.67B.
When is Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s upcoming earnings report date?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s upcoming earnings report date is Sep 02, 2026 which is in 32 days.
How were Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s earnings last quarter?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H released its earnings results on Apr 27, 2026. The company reported HK$0.267 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H overvalued?
According to Wall Street analysts Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s price is currently Undervalued.
Does Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H pay dividends?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H does not currently pay dividends.
What is Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s EPS estimate?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H have?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H has 110,781,920 shares outstanding.
What happened to Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s price movement after its last earnings report?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H reported an EPS of HK$0.267 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.917%.
Which hedge fund is a major shareholder of Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2315
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
476.71%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
61.38%
Trailing 12-Months
Company Description
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Class H, 2315) is a biotechnology company focused on antibody discovery and preclinical research capabilities built around its proprietary genetically engineered animal platforms. The company develops and commercializes fully human antibody and bispecific antibody discovery solutions and also advances selected drug candidates internally, serving pharmaceutical and biotechnology customers and partners in early-stage biologics R&D.
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (2315) Earnings & Revenues
2315 Stock 12 Month Forecast
Average Price Target
HK$62.00
▲(116.03% Upside)
Technical Analysis
Genscript Biotech
―
Wuxi Biologics (Cayman)
―
RemeGen Co. Ltd. Class H
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―